Signaling pathways and targeted therapy for pulmonary hypertension
Top Cited Papers
Open Access
- 1 July 2025
- journal article
- review article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-47
Abstract
Pulmonary hypertension (PH) is a global health issue characterized by high mortality. The main targets for current therapies in PH focus on the prostacyclin, nitric oxide, and endothelin pathways. While the approaches targeting these pathways form the foundation of standard PH treatment, the challenge remains to develop more effective therapeutic strategies. Evidence of pathological characteristics in PH illustrates other cell signaling pathways that also participate in the proliferation, apoptosis, extracellular matrix remodeling, mitochondrial dysfunction, inflammation, endothelial-to-mesenchymal transition, ferroptosis, pyroptosis, and the intricate network of cell-cell interactions of endothelial cells, smooth muscle cells, fibroblasts, and macrophages. In this review, we explore the roles of twenty key signaling pathways in PH pathogenesis. Furthermore, the crosstalks among some pathways offer a more detailed understanding of the complex mechanisms of PH. Considering the crucial role of signaling pathways in PH progression, targeting these aberrant signaling or their hub molecules offers great potential for mitigating PH pathology. This review delves into a variety of therapeutic approaches for PH that target critical signaling pathways and network interactions, including gene therapy, cell therapy, and pharmacological interventions. Supported by evidence from both animal studies and clinical trials, these strategies aim to reverse pathological alterations in pulmonary vessels and restore their normal function, addressing the significant health challenges associated with PH.Keywords
Funding Information
- National Natural Science Foundation of China (81700055)
- National Natural Science Foundation of China (81930012)
- National Natural Science Foundation of China (81930012, 81730013, 81720108003, and 82130015)
- National Natural Science Foundation of China (82130002)
This publication has 524 references indexed in Scilit:
- Diagnosis and Treatment of Pulmonary Arterial HypertensionJAMA, 2022
- The effect of chloroquine on the TRPC1, TRPC6, and CaSR in the pulmonary artery smooth muscle cells in hypoxia‐induced experimental pulmonary artery hypertensionJournal of Biochemical and Molecular Toxicology, 2020
- Endothelial to mesenchymal transition during neonatal hyperoxia‐induced pulmonary hypertensionThe Journal of Pathology, 2020
- Docosahexaenoic acid inhibits Ca2+ influx and downregulates CaSR by upregulating microRNA‐16 in pulmonary artery smooth muscle cellsJournal of Biochemical and Molecular Toxicology, 2020
- Overexpressed long noncoding RNA CPS1‐IT alleviates pulmonary arterial hypertension in obstructive sleep apnea by reducing interleukin‐1β expression via HIF1 transcriptional activityJournal of Cellular Physiology, 2019
- Berberine attenuates hypoxia‐induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor‐β signalingJournal of Cellular Physiology, 2019
- PDGF‐dependent β‐catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertensionFEBS Letters, 2015
- Meprin β, a novel mediator of vascular remodelling underlying pulmonary hypertensionThe Journal of Pathology, 2014
- Regulation of bone morphogenetic protein signalling in human pulmonary vascular developmentThe Journal of Pathology, 2007
- Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesisThe Journal of Pathology, 2001